Top Biosimilar Drug Manufacturers 2021 Profiled: Visiongain Research Inc.

Visiongain has published a new report on Top 50 Biosimilar Drug Manufacturers 2021: Profiles of Top 50 Leading Biosimilar Companies and Forecasts by Product (Adalimumab, Etanercept, Trastuzumab, Infliximab, Insulin Glargine, Rituximab, Pegfilgrastim, Epoetin Alfa, Teriparatide, Bevacizumab, Insulin Lispro, Darbepoetin Alfa, Filgrastim, Enoxaparin, Eculizumab, Natalizumab, Cetuximab, Follitropin Alfa, Somatropin, Dornase Alfa). PLUS, Regional Market Analysis AND COVID-19 Recovery Scenarios.

Top 50 Biosimilar Companies Report– Read on to determine how you can exploit the impending business opportunities emerging in this sector along with profile of top 50 companies operating in the market.

The global biosimilars market is projected to reach at a market value of USxx billion by 2023 with a lucrative CAGR during the forecast period. Visiongain’s report shows you the potential revenues streams to 2023, assessing the top 20 products, the major 50 key players, qualitative analysis, opportunities trends, and business prospects in the biosimilars industry.

Download Exclusive Sample of Report @

The company profiles are divided into three segments including:

  • Major Players: Profiles of major 15 companies that account for over 60% market share in the global biosimilars market
  • Mid-Range Players: Profiles of 20 pioneering companies that account for significant market share and focuses on the innovative strategic collaborations and M&A
  • Ones to Watch – New Players: Profiles of 15 growing companies that are investing a huge amount of money in biosimilars R&D and focuses on new drug development

Global market revenue and growth forecasts from 2020 to 2023 by product
The global biosimilars market revenue will surpass $16.57 billion in 2020 with a lucrative CAGR during the forecast period 2021-2023 to reach significant revenue growth to 2023. The major product considered in the report are:

  • Adalimumab
  • Etanercept
  • Trastuzumab
  • Infliximab
  • Insulin Glargine
  • Rituximab
  • Pegfilgrastim
  • Epoetin Alfa
  • Teriparatide
  • Bevacizumab
  • Insulin Lispro
  • Darbepoetin Alfa
  • Filgrastim
  • Enoxaparin
  • Eculizumab
  • Natalizumab
  • Cetuximab
  • Follitropin Alfa
  • Somatropin
  • Dornase Alfa
  • Other Biosimilars

Leading Companies Profiled in this Report include:

  1. AbbiVie
  2. Alvotech
  3. Amgen
  4. Apotex/Apobiologix
  5. Aryogen
  6. Aurobindo Pharma
  7. Avesthagen Ltd.
  8. Biocon
  9. Biogen
  10. Boehringer Ingelheim
  11. Celltrion
  12. Cipla
  13. Coherus BioSciences, Inc.
  14. Daiichi Sankyo Company Ltd
  15. Dr. Reddy's
  16. Egis Pharmaceuticals PLC
  17. Eli Lilly
  18. Formycon
  19. Fresenius Kabi
  20. Fujifilm Kyowa Kirin Biologics
  21. Gedeon Richter
  22. Gene Techno Science
  23. Generium
  24. Harvest Moon Pharma
  25. Hetero
  26. Intas Pharmaceuticals Ltd.
  27. Jiangsu Simcere Pharmaceutical Co., Ltd.
  28. Kashiv Pharma
  29. Ligand Pharmaceuticals
  30. Lupin
  31. Mabion
  32. Merck & Co.
  33. Mochida
  34. Mundipharma Biologics
  35. Mylan
  36. Nichi-iko
  37. Pfizer
  38. PolPharma
  39. Reliance Life Sciences
  40. Samsung Bioepis
  41. Sandoz -Novartis
  42. Sanofi
  43. Shenzhen Techdow Pharmaceutical
  44. STADA Arzneimittel AG
  45. Teva
  46. Torrent Pharma
  48. Xbrane
  49. Zhejiang Hisun Pharma
  50. Zydus Cadila

Get Detailed TOC @

How this report will benefit you
Visiongain’s new study is envisioned for anyone requiring commercial in-depth analyses for the global biosimilars market along with detailed company profiles of top 50 companies operating in the market. Our new study assists you to evaluate the overall global and regional market for biosimilars. Get the financial analysis of the overall market and major 50 player’s revenue predictions till 2023. High opportunity remains in this fast-growing Biosimilars Market. See how to exploit the existing opportunities in the market to gain maximum advantage in the near future.

In summary, this 372-page report delivers with the following knowledge:

  • Revenue forecasts from 2020 to 2023 for the global biosimilars market and sub segments (by products and region)– discover the industry’s prospects, finding the most lucrative areas for investments and revenue generation
  • Detailed profiles of Top 50 Biosimilar Companies, with financial forecasts for net revenues, operating income, R&D investment, and biosimilar segment revenue
  • Revenue forecasts from 2020 to 2023 for 5 regional markets – See forecasts for the biosimilars market in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

To access the data contained in this document please email

Information found nowhere else
With this new and exclusive report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your investment, research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Global Biosimilars market and Detailed Analysis of 50 Leading Companies. You will get the most recent data, opportunities, trends, and predictions.

Find more Visiongain research reports on Therapeutic Drug Sector click on the following links:

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help:

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10 year forecasts, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.


Sara Peerun
Commercial Director, UK
Visiongain Limited.
Tel: + 44 207 549 9987
USA Tel: 00 1 718 682 4567
EU Tel: 00 353 1 695 0006
Follow Us: LinkedIn | Twitter


SOURCE Visiongain Limited.